Global Pharmacogenomics (PGx) Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Pharmacogenomics (PGx) Market Overview

• 1.1 Product Overview and Scope of Pharmacogenomics (PGx)
• 1.2 Classification of Pharmacogenomics (PGx) by Types
  • 1.2.1 Global Pharmacogenomics (PGx) Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Pharmacogenomics (PGx) Revenue Market Share by Types in 2018
  • 1.2.3 Polymerase Chain Reaction (PCR)
  • 1.2.4 Microarray
  • 1.2.5 Sequencing
  • 1.2.6 Other
• 1.3 Global Pharmacogenomics (PGx) Market by Application
  • 1.3.1 Global Pharmacogenomics (PGx) Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Cardiovascular Diseases (CVD)
  • 1.3.3 Central Nervous System (CNS)
  • 1.3.4 Cancer/Oncology
  • 1.3.5 Infectious Diseases
  • 1.3.6 Other
• 1.4 Global Pharmacogenomics (PGx) Market by Regions
  • 1.4.1 Global Pharmacogenomics (PGx) Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Pharmacogenomics (PGx) Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Pharmacogenomics (PGx) Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Pharmacogenomics (PGx) Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Pharmacogenomics (PGx) Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Pharmacogenomics (PGx) Status and Prospect (2014-2024)
• 1.5 Global Market Size of Pharmacogenomics (PGx) (2014-2024)

2 Manufacturers Profiles

• 2.1 Abbott Laboratories
  • 2.1.1 Business Overview
  • 2.1.2 Pharmacogenomics (PGx) Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Abbott Laboratories Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Affymetrix, Inc.
  • 2.2.1 Business Overview
  • 2.2.2 Pharmacogenomics (PGx) Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Assurex Health, Inc
  • 2.3.1 Business Overview
  • 2.3.2 Pharmacogenomics (PGx) Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Astrazeneca
  • 2.4.1 Business Overview
  • 2.4.2 Pharmacogenomics (PGx) Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Astrazeneca Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 GeneDX
  • 2.5.1 Business Overview
  • 2.5.2 Pharmacogenomics (PGx) Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 GeneDX Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Illumina, Inc.
  • 2.6.1 Business Overview
  • 2.6.2 Pharmacogenomics (PGx) Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Illumina, Inc. Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Laboratory Corporation of America Holdings
  • 2.7.1 Business Overview
  • 2.7.2 Pharmacogenomics (PGx) Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Myriad Genetics, Inc.
  • 2.8.1 Business Overview
  • 2.8.2 Pharmacogenomics (PGx) Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Pathway Genomics
  • 2.9.1 Business Overview
  • 2.9.2 Pharmacogenomics (PGx) Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Pathway Genomics Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Pfizer, Inc
  • 2.10.1 Business Overview
  • 2.10.2 Pharmacogenomics (PGx) Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Pfizer, Inc Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Qiagen, Inc.
  • 2.11.1 Business Overview
  • 2.11.2 Pharmacogenomics (PGx) Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Rocheg
  • 2.12.1 Business Overview
  • 2.12.2 Pharmacogenomics (PGx) Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Rocheg Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Teva Pharmaceutical Industries Ltd.
  • 2.13.1 Business Overview
  • 2.13.2 Pharmacogenomics (PGx) Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Thermo Fisher Scientific
  • 2.14.1 Business Overview
  • 2.14.2 Pharmacogenomics (PGx) Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Transgenomic, Inc.
  • 2.15.1 Business Overview
  • 2.15.2 Pharmacogenomics (PGx) Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Revenue, Gross Margin and Market Share (2017-2018)

3 Global Pharmacogenomics (PGx) Market Competition, by Players

• 3.1 Global Pharmacogenomics (PGx) Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Pharmacogenomics (PGx) Players Market Share
  • 3.2.2 Top 10 Pharmacogenomics (PGx) Players Market Share
• 3.3 Market Competition Trend

4 Global Pharmacogenomics (PGx) Market Size by Regions

• 4.1 Global Pharmacogenomics (PGx) Revenue and Market Share by Regions
• 4.2 North America Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 4.3 Europe Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 4.5 South America Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)

5 North America Pharmacogenomics (PGx) Revenue by Countries

• 5.1 North America Pharmacogenomics (PGx) Revenue by Countries (2014-2019)
• 5.2 USA Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 5.3 Canada Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)

6 Europe Pharmacogenomics (PGx) Revenue by Countries

• 6.1 Europe Pharmacogenomics (PGx) Revenue by Countries (2014-2019)
• 6.2 Germany Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 6.3 UK Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 6.4 France Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 6.5 Russia Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 6.6 Italy Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Pharmacogenomics (PGx) Revenue by Countries

• 7.1 Asia-Pacific Pharmacogenomics (PGx) Revenue by Countries (2014-2019)
• 7.2 China Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 7.3 Japan Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 7.4 Korea Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 7.5 India Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)

8 South America Pharmacogenomics (PGx) Revenue by Countries

• 8.1 South America Pharmacogenomics (PGx) Revenue by Countries (2014-2019)
• 8.2 Brazil Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Pharmacogenomics (PGx) by Countries

• 9.1 Middle East and Africa Pharmacogenomics (PGx) Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 9.3 UAE Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Pharmacogenomics (PGx) Revenue and Growth Rate (2014-2019)

10 Global Pharmacogenomics (PGx) Market Segment by Type

• 10.1 Global Pharmacogenomics (PGx) Revenue and Market Share by Type (2014-2019)
• 10.2 Global Pharmacogenomics (PGx) Market Forecast by Type (2019-2024)
• 10.3 Polymerase Chain Reaction (PCR) Revenue Growth Rate (2014-2024)
• 10.4 Microarray Revenue Growth Rate (2014-2024)
• 10.5 Sequencing Revenue Growth Rate (2014-2024)
• 10.6 Other Revenue Growth Rate (2014-2024)

11 Global Pharmacogenomics (PGx) Market Segment by Application

• 11.1 Global Pharmacogenomics (PGx) Revenue Market Share by Application (2014-2019)
• 11.2 Pharmacogenomics (PGx) Market Forecast by Application (2019-2024)
• 11.3 Cardiovascular Diseases (CVD) Revenue Growth (2014-2019)
• 11.4 Central Nervous System (CNS) Revenue Growth (2014-2019)
• 11.5 Cancer/Oncology Revenue Growth (2014-2019)
• 11.6 Infectious Diseases Revenue Growth (2014-2019)
• 11.7 Other Revenue Growth (2014-2019)

12 Global Pharmacogenomics (PGx) Market Size Forecast (2019-2024)

• 12.1 Global Pharmacogenomics (PGx) Market Size Forecast (2019-2024)
• 12.2 Global Pharmacogenomics (PGx) Market Forecast by Regions (2019-2024)
• 12.3 North America Pharmacogenomics (PGx) Revenue Market Forecast (2019-2024)
• 12.4 Europe Pharmacogenomics (PGx) Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Pharmacogenomics (PGx) Revenue Market Forecast (2019-2024)
• 12.6 South America Pharmacogenomics (PGx) Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Pharmacogenomics (PGx) Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology